

A

concentration dependant angle changes, upon the interaction of various concentrations of BoNT/A with immobilized antibody and the Figure 2A depicts the corresponding calibration curve. The limit of detection (LOD) of the present method was calculated experimentally and was found to be 0.045 fM and this is the minimum concentration of BoNT/A antigen which showed the response during the interaction of BoNT/A antigen with its immobilized antibody.

Binding of different concentration of BoNT/A antigen was also carried out with immobilized SV protein in order to know the biological activity of purified protein and the sensorgrams are shown in Figure 2B. Figure 3 represents the comparative response of binding of BoNT/A and BSA with immobilized SV. BSA was used as negative control and showed 63% binding with immobilized SV in comparison of BoNT/A as shown in Figure 3.

Evaluation of kinetics involved in the antigen and antibody interaction

The affinity interactions between immobilized BoNT/A antibody and BoNT/A antigen were characterized by the equilibrium constant (K_D). The data were fitted using a simple 1:1 interaction model [37], $A + B = AB$, where 'A' is the injected analyte, 'B' is the immobilized ligand and 'AB' is the analyte–ligand complex formed during the interaction process. In the SPR system, the signal R is proportional to the amount of (AB) and the R_{max} is proportional to the initial (B). Hence, in this study kinetic parameters such as k_{on} and B_{max} value were calculated

Evaluation of thermodynamic parameters

The K_D obtained from kinetic evaluation so far was further exploited to calculate the thermodynamic parameters such as change in Gibbs free energy (ΔG), change in enthalpy (ΔH) and change in entropy (ΔS) associated with binding of BoNT/A antigen with immobilized antibody using Van't Hoff [39,40] equation:

$$\Delta G = -RT \ln K_A = \Delta H - T\Delta S \quad (1)$$

$$\Delta H = R \left(\frac{T_1 T_2}{T_2 - T_1} \right) \ln \left(\frac{K_A(T_1)}{K_A(T_2)} \right) \quad (2)$$

$$K_A = \frac{K_D}{R} \quad (3)$$

where, R: universal gas constant, K_A : affinity constant, T: temperature and K_1, K_2 are affinity constants for association at T_1 and T_2 temperature, respectively. ΔG , ΔH and ΔS are change in Gibbs free energy, change in the enthalpy and change in the entropy due to the binding of BoNT/A with immobilized BoNT/A antibody, respectively.

The value of the change in Gibbs free energy for binding of BoNT/A with immobilized BoNT/A antibody, was found to be -84.99 kJ/mol at 298 K. The negative value of ΔG indicates the spontaneous interaction of BoNT/A antigen with its antibody.

The calculated value of ΔH using Van't Hoff Wizard in kinetic evaluation so far was found to be +16.33 kcal/mol. The positive value of ΔH reveals the interaction of BoNT/A with immobilized BoNT/A antibody as endothermic [41].

The value of ΔS for binding of BoNT/A with immobilized BoNT/A antibody was calculated using so far and was found to be 207.43 cal mol⁻¹ K⁻¹. The magnitude of $T\Delta S$ value was found to be higher than ΔH indicating that the net influence of enthalpy on the BoNT/A with immobilized BoNT/A antibody is minor and the apparent gain in entropy is actually the driving force for the BoNT/A with immobilized BoNT/A antibody [42,43]. The observed positive value in entropy indicated that the interaction can be explained by Langmuir replacement reaction that exhibits Langmuir type isotherm [38]. Langmuir replacement reaction suggests that the observed positive entropy is because of desorption of water molecules from either antibody or antigen or both. The significance of desorption of water molecules from protein surfaces during ligand-protein binding was reported earlier [43].

Effect of temperature

Temperature variation study was performed in order to know the effect of temperature on SPR response during the interaction of antibody with antigen. Upon increasing temperature from 10 to 25°C an increase in SPR angle is observed as shown in Figure 4A and beyond 25°C, SPR angle decreased. Hence, 25°C is used as optimum temperature for the interaction of BoNT/A antigen with its immobilized antibody.

Effect of pH

Figure 4B shows the effect of pH on SPR angle due to the interaction of BoNT/A antigen with its immobilized antibody. It is observed from Figure 4B that SPR response exhibits a maximum at pH 7.5. This result can also be explained by considering the effect of pI of the antigen and antibody. The pI of the antigen is 5.5 and the pI of the antibody is 7.5. The result can also be explained by considering the effect of pI of the antigen and antibody. The pI of the antigen is 5.5 and the pI of the antibody is 7.5.

4. Lacy DB, Tepp W, Cohen AC, Gupta BRD, Stevens RC (1998) Crystal structure of botulinum neurotoxin type A and implications for toxicity. *Nat Struct Biol* 5: 898-902.
5. Kitamura M, Takamiya K, Aizawa S, Furukawa K (1999) Gangliosides are the binding substances in neural cells for tetanus and botulinum toxins in mice. *Biochim Biophys Acta* 1441: 1-3.
6. Kozaki S, Kamata Y, Watarai S, Nishiki T, Mochida S (1998) Ganglioside GT1b as a complementary receptor component for Clostridium botulinum neurotoxins. *Microb Pathog* 25: 91-99.
7. Li L, Singh BR (1998) Isolation of synaptotagmin as a receptor for types A and E botulinum neurotoxin and analysis of their comparative binding using a new microtiter plate assay. *J Nat Toxins* 7: 215-226.
8. Ginalski K, Venclovas C, Lesyng B, Fidelis K (2000) Structure-based sequence alignment for the beta trefoil subdomain of the clostridial neurotoxin family provides residue level information about the putative ganglioside binding site. *FEBS Lett* 482: 119-124.
9. Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, et al. (2001) Botulinum toxin as a biological weapon: medical and public health management. *JAMA* 285: 1059-1070.
10. Bigalke H, Rummel A (2005) Medical aspects of toxin weapons. *Toxicology* 214: 210-220.

parameter to reflect the in-situ changes those are occurring on the modified disc/electrolyte interface, hence, the fitting and simulation method was adopted to find out the Ret value for CM5 gold disc and antibody immobilized CM5 gold chip before and after antigen interaction, the Ret values are found to be 2.79 M Ω , 466 k Ω and 440 k Ω , respectively. The decrease in Ret value after the interaction of antigen with antibody directly confirms an increase in electron transfer due to the effective binding of antigen with antibody because of the presence of good interaction at this pH (7.5) as reported earlier for an antigen antibody interaction [44].

Conclusion

A label free real time SPR detection methodology for BoNT/A was developed using a carboxymethyl dextran modified sensor chip. The effective interaction between the antigen and antibody was confirmed based on EIS data as a decrease in charge transfer resistance was observed due to the effective interaction between BoNT/A antigen and antibody. The LOD of the developed method is 0.045 fM. The SPR sensor gram of the binding of BoNT/A with immobilized SV confirmed the biological activity of purified protein. The kinetic parameters such as k_{on} and B_{max} values were calculated and found to be 0.53 fM and 38.23 μ M for immobilized antibody and 0.22 fM and 116.0 nM for immobilized SV, respectively. The K_{d} value of 20.53 fM implies and classifies this antibody as a high affinity one. The negative value change in Gibbs free energy indicates the spontaneous nature of interaction of BoNT/A antigen with immobilized antibody and SV and the positive value revealed the interaction of BoNT/A with immobilized antibody as endothermic. The positive value of ΔS was found to be greater than 2 J/K indicating the interaction of BoNT/A with its immobilized antibody as entropy driven. This study gives inputs for the development of SPR based sensors using antigen and antibody interaction for BoNT/A and other BWAs.

References

1. Sakaguchi G (1982) Clostridium botulinum toxins. *Pharmacol* 19: 165-194.
2. Hambleton P (1992) Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use. *J Neurol* 239: 16-20.
3. Turton K, Chaddock JA, Acharya KR (2002) Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. *Trends Biochem Sci* 27: 552-558.
11. Johnson EA (2003) Bacterial Pathogens and Toxins in Foodborne Disease. In *Food Safety: Contaminants and Toxins* pp: 25-45.
12. Yowler BC, Schengrund CL (2004) Botulinum neurotoxin A conformation upon binding to ganglioside GT1b. *Biochemistry* 43: 9725-9731.
13. Pless DD, Torres ER, Reinke EK, Bavari S, et al. (2005) Antibodies to the binding domain of botulinum neurotoxin type A, *Infection and Immunity* 69: 570-574.
14. Ferracci G, Miquelis R, Kozaki S, Seagar M, Leveque C (2005) Synaptic vesicles chips to assay botulinum neurotoxins. *J Biochem* 391: 659-666.
15. Marconi S, Ferracci G, Berthomieu M, Kozaki S, Miquelis R, et al. (2008) A protein chip membrane capture assay for botulinum neurotoxin activity. *Toxicology and Applied Pharmacology* 233: 439-446.
16. Doellgast GJ, Triscott MX, Beard GA, Bottoms JD, Cheng T, et al. (1993) Sensitive enzyme-linked immunosorbent assay for detection of Clostridium botulinum neurotoxin type A in therapeutic preparations. *J Immunol Methods* 180: 181-191.
17. Wang TA, Mc Lellan K, Sesardic D (1995) Immunological detection of Clostridium botulinum toxin type A in therapeutic preparations. *J Immunol Methods* 180: 181-191.
18. Szilagyi M, Rivera VR, Neal D, Merrill GA, Poli MA (2000) Development of sensitive colorimetric capture ELISAs for Clostridium botulinum neurotoxin serotypes A and B. *Toxicon* 38: 381-389.
19. Schmidt JJ, Stafford RG, Millard CB, (2001) High throughput assays for botulinum neurotoxin proteolytic activity: serotypes A, B, D, and F, *Anal Biochem* 296 130-137.
20. Chiao DJ, Shyu RH, Hu CS, Chiang HY, Tang SS (2004) Colloidal gold-based immunochromatographic assay for detection of botulinum neurotoxin type B. *J Chromatogr B Analyt Technol Biomed Life Sci* 809: 37-41.
21. Wang TA, Mc Lellan K, Sesardic D (1995) Immunological detection of Clostridium botulinum toxin type A in therapeutic preparations. *J Immunol Methods* 180: 181-191.
22. Gessler F, Hampe K, Bohnel H (2005) Sensitive detection of botulinum neurotoxin A and staphylococcal enterotoxin B in food. *Appl Environ Microbiol* 71: 7897-7903.
23. Sapsford KE, Taitt CR, Loo N, Ligler FS (2005) Biosensor detection of botulinum neurotoxin A and staphylococcal enterotoxin B in food. *Appl Environ Microbiol* 71: 5590-5992.
24. Sharma SK, Eblen BS, Bull RL, Burr DH, Whiting RC (2005) Evaluation of biosensors for detection of botulinum neurotoxin A and staphylococcal enterotoxin B in food. *Appl Environ Microbiol* 71: 3935-3941.
25. ...

detection. *Anal Biochem* 353: 248-256.

26. Cherif B, Roget A, Villiers CL, Calemczuk R, Leroy V, Marche PN, Livache T, Villiers MB (2006) Clinically related protein-peptide interactions monitored in

